| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 97 | 7.7x | 17.8x | Top tier | |
Growth | 39 | 5.5% | 7.1% | Bottom tier | |
Quality | 97 | 24.7% | 4.5% | Top tier | |
Safety | 42 | 2.9x | 2.6x | Around median | |
Capital Return | 94 | — | 2.12% | Top tier | |
Momentum | 32 | 33.8% | 2.9% | Bottom tier | |
Sentiment | 50 | 2 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Herbalife Nutrition Ltd. sells health, wellness, and nutrition products through a global network comprising more than two million distributors, more than 60 thousand Nutrition Clubs, and millions of customers across 95 markets. Its model relies on distributor recommendations and direct customer relationships, while the company is expanding its portfolio from general products to nutrition tailored to individual data through Protocol, Vionic, Link Biosciences, and Prüvit. This ecosystem aims to connect health measurements, recommendations, products, and daily habits, while adding subscriptions and e-commerce to the existing sales model.
In Q1 fiscal 2026, revenue reached $1.3 billion, up 7.8% year over year on a reported basis and 5.4% in constant currency, while global volume rose 4.1%. Gross profit was approximately $1.0 billion, with a gross margin of 77.9%, representing a year-over-year decline of 40 basis points, while net income was $61.9 million and earnings per share were $0.57, according to EDGAR data. Adjusted EBITDA was $176 million, with a margin of 13.3%, exceeding management's guidance range of $155–175 million.
The geographic mix was uneven in Q1 fiscal 2026: Asia Pacific sales rose 17%, and India achieved a record $275 million, with reported growth of 32%, while Latin America also grew 17%. In contrast, Europe, the Middle East, and Africa rose only 1% on a reported basis and declined 6% in constant currency, while North America fell 3% and China declined 12%. This mix shows that acceleration in India and Latin America offset weakness in Western markets and China.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $17, with a “Buy” consensus, but the highest and lowest targets are identical at $17, meaning the data do not provide a diverse range of valuation estimates. This target is approximately 16.7% below the 52-week range high of $20.40 and approximately 125% above the range low of $7.56. The valuation therefore depends primarily on the continuation of the operational recovery and leverage reduction, balanced against the risks of a slowdown in India, weakness in Europe and China, and margin contraction.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
Herbalife's revenue reached approximately $1.3 billion, up 7.8% year over year on a reported basis and 5.4% in constant currency. Global volume rose 4.1%, pricing added approximately $40 million, and currency provided a positive impact of approximately $29 million. India was the most significant driver, with record sales of $275 million and reported growth of 32%, while Asia Pacific and Latin America each recorded reported growth of 17%.
In April 2026, the company completed a $1.45 billion secured refinancing, including $800 million of notes due in May 2033, a $225 million term loan, and a $425 million revolving facility. Management expects the new structure to reduce cash interest payments by approximately $45 million annually, with no significant maturities before 2028. Total leverage was 2.7 times and net leverage was 2.1 times as of March 31, 2026, and management is targeting net leverage below 2 times by the end of fiscal 2026.
On April 30, 2026, Herbalife completed the acquisition of most of the assets of Vionic's core personalized nutrition business, a British company with a patented engine for designing supplements based on health background and biomarker data. The base payments total $55 million over five years, with potential payments of up to $95 million tied to the sales performance of Vionic products. Management planned to begin offering personalized vitamin and mineral formulations through distributors in 11 European countries in late June 2026, followed by the United States in July 2026.
Protocol was still in the testing phase at the time of the May 6, 2026 call, after the program was expanded to ten selected markets in Europe, the Middle East, and Africa during March 2026. Management said it had not included any direct revenue from Protocol or Vionic in its fiscal 2026 outlook. The platform aims to connect health measurements, data, recommendations, and personalized products, but its use within Nutrition Clubs and the integration of certain commerce and subscription functions were still at an early stage.
Sales in Europe, the Middle East, and Africa declined 6% in constant currency in Q1 fiscal 2026, with volume down 11%. North America sales fell 3% and volume declined 5%, although management said severe weather and in-transit shipments at quarter-end affected the timing of revenue recognition. In China, reported sales declined 12% and volume fell 18%; the market represents approximately 4% of group sales and does not make a meaningful profit contribution, according to management.
Management expects reported revenue growth of between 1.5% and 5.5% in fiscal 2026 and between 1% and 5% in constant currency. It expects adjusted EBITDA of between $675 million and $705 million, capital expenditures of between $50 million and $80 million, and capitalized software implementation costs of between $35 million and $55 million. It also expects an adjusted effective tax rate of approximately 30% and a $20 million to $25 million headwind from the goods and services tax mismatch in India.
